Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Meister

Showing results (101-110 of 117) with videos related to

Pageof 12
Sort By:
Oncoimmunology|February 1, 2021
A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinomaJan Budczies, Martina Kirchner, Klaus Kluck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancerPaul Roepman, Jacek Jassem, Egbert F Smit, et al.
Therapeutic Advances in Medical Oncology|August 19, 2021
Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancerNikolaus Magios, Farastuk Bozorgmehr, Anna-Lena Volckmar, et al.
International Journal of Cancer|January 25, 2018
EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK<sup>+</sup> non-small cell lung cancerPetros Christopoulos, Volker Endris, Farastuk Bozorgmehr, et al.
Cancers|January 24, 2019
Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor SurvivalPetros Christopoulos, Steffen Dietz, Martina Kirchner, et al.
Cell|October 5, 2024
Identifying specific functional roles for senescence across cell typesHuan Zhao, Zixin Liu, Hui Chen, et al.
Translational Lung Cancer Research|September 21, 2020
Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectivesSabine Wessels, Thomas Muley, Petros Christopoulos, et al.
Ebiomedicine|November 8, 2020
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNASteffen Dietz, Petros Christopoulos, Zhao Yuan, et al.
Cancers|May 28, 2022
Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNAStephanie J Yaung, Corinna Woestmann, Christine Ju, et al.
Cancer Immunology, Immunotherapy : CII|June 14, 2021
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinomaJan Budczies, Martina Kirchner, Klaus Kluck, et al.
Pageof 12

Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
Oncoimmunology|February 1, 2021
A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinomaJan Budczies, Martina Kirchner, Klaus Kluck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancerPaul Roepman, Jacek Jassem, Egbert F Smit, et al.
Therapeutic Advances in Medical Oncology|August 19, 2021
Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancerNikolaus Magios, Farastuk Bozorgmehr, Anna-Lena Volckmar, et al.
International Journal of Cancer|January 25, 2018
EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK<sup>+</sup> non-small cell lung cancerPetros Christopoulos, Volker Endris, Farastuk Bozorgmehr, et al.
Cancers|January 24, 2019
Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor SurvivalPetros Christopoulos, Steffen Dietz, Martina Kirchner, et al.
Cell|October 5, 2024
Identifying specific functional roles for senescence across cell typesHuan Zhao, Zixin Liu, Hui Chen, et al.
Translational Lung Cancer Research|September 21, 2020
Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectivesSabine Wessels, Thomas Muley, Petros Christopoulos, et al.
Ebiomedicine|November 8, 2020
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNASteffen Dietz, Petros Christopoulos, Zhao Yuan, et al.
Cancers|May 28, 2022
Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNAStephanie J Yaung, Corinna Woestmann, Christine Ju, et al.
Cancer Immunology, Immunotherapy : CII|June 14, 2021
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinomaJan Budczies, Martina Kirchner, Klaus Kluck, et al.
Pageof 12